183 related articles for article (PubMed ID: 20462442)
1. Evaluation of neuroendocrine markers in renal cell carcinoma.
Ronkainen H; Soini Y; Vaarala MH; Kauppila S; Hirvikoski P
Diagn Pathol; 2010 May; 5():28. PubMed ID: 20462442
[TBL] [Abstract][Full Text] [Related]
2. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
3. Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma.
Mjønes PG; Nordrum IS; Qvigstad G; Sørdal Ø; Rian LL; Waldum HL
APMIS; 2017 Mar; 125(3):213-222. PubMed ID: 28233444
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
5. Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; Thomas M; Winter H; Eichhorn M; Eichhorn F; von Winterfeld M; Herpel E; Goeppert B; Stenzinger A; Herth FJF; Warth A; Kriegsmann M
BMC Cancer; 2021 May; 21(1):486. PubMed ID: 33933015
[TBL] [Abstract][Full Text] [Related]
6. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine markers; chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell carcinoma.
Edgren M; Stridsberg M; Kalknar KM; Nilsson S
Anticancer Res; 1996; 16(6B):3871-4. PubMed ID: 9042273
[TBL] [Abstract][Full Text] [Related]
8. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
9. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
Wu Y; Lai Y; Zhang M; Li Z
Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
[TBL] [Abstract][Full Text] [Related]
11. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma.
Ronkainen H; Vaarala MH; Kauppila S; Soini Y; Paavonen TK; Rask J; Hirvikoski P
Oncol Rep; 2009 Jun; 21(6):1519-23. PubMed ID: 19424632
[TBL] [Abstract][Full Text] [Related]
12. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
Chen JF; Yang C; Sun Y; Cao D
Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
[TBL] [Abstract][Full Text] [Related]
13. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases.
Lu J; Xue LY; Lu N; Zou SM; Liu XY; Wen P
Dis Esophagus; 2010 Feb; 23(2):153-9. PubMed ID: 19515193
[TBL] [Abstract][Full Text] [Related]
14. Frequent expression of neuroendocrine markers in mucinous tubular and spindle cell carcinoma of the kidney.
Kuroda N; Hes O; Miyazaki E; Shuin T; Enzan H
Histol Histopathol; 2006 Jan; 21(1):7-10. PubMed ID: 16267782
[TBL] [Abstract][Full Text] [Related]
15. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of intratumoral C-reactive protein expression in patients with clear cell renal cell carcinoma.
Can C; Acikalin MF; Ozen A; Dundar E
Urol Int; 2014; 92(3):270-5. PubMed ID: 24356040
[TBL] [Abstract][Full Text] [Related]
17. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
[TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma with rhabdoid features.
Gökden N; Nappi O; Swanson PE; Pfeifer JD; Vollmer RT; Wick MR; Humphrey PA
Am J Surg Pathol; 2000 Oct; 24(10):1329-38. PubMed ID: 11023094
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of insulin- like growth factor-I receptor expression in renal cell carcinoma.
Sichani MM; Yazdi FS; Moghaddam NA; Chehrei A; Kabiri M; Naeimi A; Taheri D
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):69-74. PubMed ID: 20061696
[TBL] [Abstract][Full Text] [Related]
20. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.
Mjønes P; Sagatun L; Nordrum IS; Waldum HL
J Histochem Cytochem; 2017 Dec; 65(12):687-703. PubMed ID: 28972818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]